Protocol Ledger

NCT05534087 · Phase III · RECRUITING

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

Interventional Phase III clinical trial protocol NCT05534087 sponsored by Seoul National University Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-15 Enrollment: 236 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05534087
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)236 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05534087
Protocol FieldVerified Registry Value
NCT IdentifierNCT05534087
Consolidated Lead SponsorSeoul National University Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment236 participants (ESTIMATED)
Registered Start Date2022-12-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05534087
Hospital Research SiteLocationSite Profile
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Kyungpook National University Chilgok HospitalDaegu, South KoreaOpen Hospital Dossier ->
Chonnam National University Hwasun HospitalHwasun, South KoreaOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI